Ysios Capital has gone above and beyond and raised €126M that will be directed to early-stage and development-phase Biotechs to help translate the country’s leading research into the market.
Ysios Capital is a leading Biotech VC in Spain that made it to our 2016 Top European VCs. Last week, Ysios added €126.4M to its second fund, Ysios Biofund II Innvierte, making a total of €191.4M under its management. The amount has exceeded the VC’s target of €100M and has established the fund as one of the biggest Biotech funds in Southern Europe.
Ysios has managed to build the trust of its investors with €100M in capital in 2015 alone through its portfolio companies. The investors include the Spanish Ministry of Economy, the European Investment Fund (EIF), the European Commission, national banks and several other private investors.
Ysios expects to fund up to 15 companies with an average investment of €8-10M. Although not exclusively, the focus will be on national companies that are in the early stage and development phase, for which financing options are usually limited.
The fund has already invested in 5 companies, including Sanifit, which last year took home the largest Biotech financing round in Spain’s history. The other Spanish recipients are Minoryx Therapeutics, working in metabolic diseases, and Aelix Therapeutics, which focuses in HIV cures.
New investments will be announced before the end of the year, which the partners expect to be an inflection point in Spain’s Biotech sector. Despite its strong position in research, the country struggles with translation into the market and insufficient support to reach global influence. With this outstanding fundraising, the South is one step closer to gain its place among the top players in Europe.
Featured image: Holbox/shutterstock.com
Image 1 courtesy of Ysios Capital